California Public Employees Retirement System lowered its position in Agenus Inc (NASDAQ:AGEN) by 10.6% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 127,253 shares of the biotechnology company’s stock after selling 15,064 shares during the quarter. California Public Employees Retirement System’s holdings in Agenus were worth $303,000 as of its most recent SEC filing.

Other institutional investors have also recently modified their holdings of the company. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in Agenus by 272.8% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 32,105 shares of the biotechnology company’s stock worth $76,000 after acquiring an additional 23,493 shares during the last quarter. Virtu Financial LLC purchased a new position in Agenus in the third quarter worth approximately $105,000. Rhumbline Advisers lifted its stake in Agenus by 50.3% in the fourth quarter. Rhumbline Advisers now owns 112,015 shares of the biotechnology company’s stock worth $267,000 after acquiring an additional 37,463 shares during the last quarter. Jefferies Group LLC lifted its stake in Agenus by 171.2% in the third quarter. Jefferies Group LLC now owns 166,523 shares of the biotechnology company’s stock worth $356,000 after acquiring an additional 105,123 shares during the last quarter. Finally, Wells Fargo & Company MN lifted its stake in Agenus by 26.7% in the third quarter. Wells Fargo & Company MN now owns 941,284 shares of the biotechnology company’s stock worth $2,015,000 after acquiring an additional 198,247 shares during the last quarter. Institutional investors own 28.39% of the company’s stock.

AGEN stock opened at $2.75 on Thursday. Agenus Inc has a twelve month low of $1.54 and a twelve month high of $4.80. The company has a market cap of $378.46 million, a price-to-earnings ratio of -1.91 and a beta of 2.07.

Agenus (NASDAQ:AGEN) last released its quarterly earnings data on Thursday, March 14th. The biotechnology company reported ($0.40) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.12). The business had revenue of $5.36 million for the quarter, compared to the consensus estimate of $6.67 million. Sell-side analysts expect that Agenus Inc will post -1.27 EPS for the current year.

AGEN has been the subject of a number of recent research reports. ValuEngine upgraded shares of Agenus from a “hold” rating to a “buy” rating in a research note on Thursday, January 17th. BidaskClub raised shares of Agenus from a “hold” rating to a “buy” rating in a report on Thursday, January 10th. Finally, Zacks Investment Research cut shares of Agenus from a “hold” rating to a “sell” rating in a report on Tuesday, January 8th.

ILLEGAL ACTIVITY NOTICE: This piece of content was published by Watch List News and is the sole property of of Watch List News. If you are accessing this piece of content on another publication, it was illegally copied and reposted in violation of United States and international copyright laws. The correct version of this piece of content can be read at https://www.watchlistnews.com/california-public-employees-retirement-system-sells-15064-shares-of-agenus-inc-agen/2953950.html.

About Agenus

Agenus Inc, a clinical-stage immuno-oncology company, focuses on the discovery and development of therapies that engage the body's immune system to fight cancer. The company offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized monoclonal antibodies; SECANT yeast display, an antibody discovery platform used for the generation of novel monoclonal antibodies; and phage display technologies.

Recommended Story: Market Capitalization in the Stock Market

Want to see what other hedge funds are holding AGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Agenus Inc (NASDAQ:AGEN).

Institutional Ownership by Quarter for Agenus (NASDAQ:AGEN)

Receive News & Ratings for Agenus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus and related companies with MarketBeat.com's FREE daily email newsletter.